Wall Street brokerages predict that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will report earnings of ($0.02) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with estimates ranging from ($0.16) to $0.36. Pieris Pharmaceuticals posted earnings per share of ($0.19) in the same quarter last year, which would indicate a positive year-over-year growth rate of 89.5%. The company is expected to report its next quarterly earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.65) to ($0.28). For the next financial year, analysts forecast that the firm will report earnings of ($0.77) per share, with EPS estimates ranging from ($1.00) to ($0.61). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Friday, March 9th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.21. Pieris Pharmaceuticals had a negative net margin of 69.82% and a negative return on equity of 162.54%. The firm had revenue of $18.15 million during the quarter, compared to the consensus estimate of $7.63 million.
In other news, major shareholder Orbimed Advisors Llc sold 7,897 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $8.98, for a total transaction of $70,915.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.05% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of PIRS. Creative Planning grew its holdings in shares of Pieris Pharmaceuticals by 18.2% during the 4th quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after purchasing an additional 12,000 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Pieris Pharmaceuticals by 14.0% during the 4th quarter. Acadian Asset Management LLC now owns 116,154 shares of the biotechnology company’s stock worth $877,000 after purchasing an additional 14,263 shares during the period. Cetera Advisor Networks LLC purchased a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth about $124,000. New York State Common Retirement Fund grew its holdings in shares of Pieris Pharmaceuticals by 107.5% during the 3rd quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 17,100 shares during the period. Finally, Wells Fargo & Company MN purchased a new stake in shares of Pieris Pharmaceuticals during the 3rd quarter worth about $105,000. 43.99% of the stock is owned by institutional investors.
PIRS stock traded down $0.10 during trading on Monday, hitting $6.23. The stock had a trading volume of 420,203 shares, compared to its average volume of 881,885. Pieris Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $9.75. The company has a market capitalization of $340.90, a price-to-earnings ratio of -15.58 and a beta of 1.71.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3344368/zacks-analysts-expect-pieris-pharmaceuticals-inc-pirs-will-announce-earnings-of-0-02-per-share.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.